Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs intermittent beta-lactam infusion in critically ill sepsis patients
2017-004637-85Phase 4Completed
- Sponsor
- The George Institute for Global Health
- Start
- Nov 2018
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of piperacillin + tazobactam and meropenem in sepsis (2 arms), sponsored by The George Institute for Global Health. Primary endpoint: All-cause mortality at Day 90. Started Nov 2018; status: completed.
02
Drugs
piperacillin + tazobactammeropenem
03
Conditions
sepsis
Beyond the preview
Go deeper on 2017-004637-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004637-85.